本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

IX生物制药

0.020
0.000
成交量:7.39万
成交额:1,411.80
市值:1,775.92万
市盈率:-1.72
高:0.020
开:0.018
低:0.018
收:0.020
52周最高:0.029
52周最低:0.015
股本:8.88亿
流通股本:4.78亿
量比:0.30
换手率:0.02%
股息:- -
股息率:- -
每股收益(TTM):-0.012
每股收益(LYR):-0.012
净资产收益率:-431.07%
总资产收益率:-30.32%
市净率:48.66
市盈率(LYR):-1.73

数据加载中...

公司资料

公司名字:
IX生物制药
交易所:
SGX
成立时间:
2004
员工人数:
42
公司地址:
No. 14-01 Great World City East Lobby,1 Kim Seng Promenade,Singapore,Singapore
邮编:
237994
电话:
传真:
65 6235 2170
简介:
IX Biopharma Ltd. is a Singapore-based specialty pharmaceutical and nutraceutical company. The Company is focused on the development, manufacturing and commercialization of innovative therapies for the treatment of acute and breakthrough pain, and other health conditions. It has developed a patented drug delivery platform technology, WaferiX. WaferiX is a novel multi-drug delivery platform comprising a highly porous, amorphous and non-ionic matrix in a solid dosage form. The Company operates through two segments: Specialty Pharmaceutical and Nutraceutical segments. Specialty Pharmaceutical primary business activities are the development, manufacturing and sale of pharmaceutical and medicinal cannabis products. Nutraceutical primary business activities are the sale of nutraceutical products. The Company's pipeline of products under development includes Wafermine (ketamine wafer) and BnoX (buprenorphine wafer) for pain management.